arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

TriSalus Life Sciences, Inc.

TLSI
$5.59 ▲ +0.75 (+15.50%) at close
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
23 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
54
Health
Fair
Neutral
auto_awesome

Analytical Summary

TriSalus Life Sciences, Inc. demonstrates solid fundamentals with strength in Return on Common Equity (%). Overall, the data suggests a moderately positive outlook with manageable risks.

Market Cap $288.1M
Dividend Yield
Revenue Growth -2.9%
Op. Margin -94.5%
ROIC -18.3%
FCF / Share $-0.13
Trailing P/E 186.3x
Price / Book 26.8x
FCF Yield
Debt / Equity 2.58
info Valuation on last close. End-of-day price, Aug 7, 2026.

23-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$8.90M
↓ -2.9%
Net Income Profit after all expenses
$1.54M
↑ +115.8%
Operating Margin Operating profit as % of sales
-94.5%
↓ -281.6% 4th
FCF / Share Free cash flow per share
$-0.13
↑ +30.2%
Long-Term Debt Long-term obligations
$33.08M
— +0.1%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
4
Returns
99
Financial Health
67
Cash Quality
39

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 6 years · 23 quarters